http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
-
Spruce Biosciences (SPRB) Appoints Percival Barretto-Ko to its Board
-
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
-
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
-
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
-
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
-
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
-
Spruce Biosciences to Participate in May Investor Conferences
-
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
-
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
-
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
-
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
-
Spruce Biosciences (SPRB), Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
-
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
-
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
-
Spruce Biosciences to Participate in November Investor Conferences
-
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Spruce Biosciences to Participate in June Investor Conferences
-
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
-
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Spruce Biosciences to Participate in May Investor Conferences
-
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
-
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
-
Spruce Biosciences (SPRB) Appoints Will Charlton as Chief Medical Officer
-
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
-
Spruce Biosciences to Participate in March Investor Conferences
-
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
-
Spruce Biosciences (SPRB) Provides Clinical Program Updates and Outlook for 2022
-
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
-
Spruce Biosciences (SPRB) Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
-
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
-
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
-
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
-
Spruce Biosciences (SPRB) Appoints Mike Grey as New Interim CEO
-
Spruce Biosciences Appoints Mike Grey as Interim CEO
-
Spruce Biosciences to Participate in September Investor Conferences
-
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
-
Spruce Biosciences to Host Virtual R&D Day on August 25, 2021
-
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
-
Spruce Biosciences (SPRB) Appoints Kirk Ways to its Board
-
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
-
Spruce Biosciences (SPRB) Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
-
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
-
Spruce Biosciences (SPRB) Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
-
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
-
Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference
-
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates

